Summary
Several claims are not directly supported by the provided label excerpts because the excerpts do not include specific liver laboratory monitoring language, hepatic impairment dosing guidance details for liver enzymes, or statements about the frequency/uncommonness or permanence of liver injury. Some liver-test-related monitoring and dose modification concepts are partially supported generally via hepatic impairment dose modification and general CBC monitoring, but liver-enzyme monitoring and specific risk framing are unsupported.
Category Scores
Accurate Statements
Elevated liver enzymes with Jakafi can indicate liver irritation or injury.
Not directly supported in the provided excerpts; however, hepatic impairment is addressed (8.7) and exposure increases with hepatic impairment, implying hepatic relevance. No explicit mapping from enzyme elevations to irritation/injury is present.
Unsupported Statements
Jakafi (ruxolitinib) can cause liver-related side effects.
Provided excerpts do not include explicit liver-related adverse effects (e.g., hepatitis, liver injury, hepatic adverse reactions) or liver side effect language.
Jakafi can cause elevated liver enzymes during treatment.
No explicit statement in the provided excerpts about elevated liver enzymes during treatment.
Elevated liver enzymes with Jakafi can indicate liver irritation or injury.
No provided excerpt links liver enzyme elevations to irritation or injury.
Jakafi can, less commonly, cause liver function problems.
No provided excerpt provides a frequency or relative likelihood ('less commonly') for liver function problems.
In clinical use, liver enzyme increases are monitored during Jakafi treatment.
The only explicit monitoring frequency in provided text is CBC (2 to 4 weeks) and lipid parameters; no explicit liver enzyme monitoring schedule is provided.
Jakafi label emphasizes regular laboratory monitoring for liver tests.
Provided excerpts do not state regular laboratory monitoring specifically for liver tests.
Liver enzyme elevations with Jakafi are a known risk.
No explicit 'known risk' language for liver enzyme elevations is present in provided excerpts.
Jakafi label describes increases in alanine aminotransferase (ALT).
No provided excerpt mentions ALT.
Jakafi label describes increases in aspartate aminotransferase (AST).
No provided excerpt mentions AST.
Jakafi label describes increases in bilirubin.
No provided excerpt mentions bilirubin increases.
Jakafi label reports dose-related patterns of ALT, AST, and bilirubin increases.
No provided excerpt mentions ALT/AST/bilirubin or dose-related patterns for these.
Treatment adjustments may be needed depending on the severity of abnormal liver laboratory results for Jakafi.
Provided excerpt indicates hepatic impairment dose modifications exist, but it does not provide liver-lab abnormality severity-based adjustment instructions in the excerpted text.
Clinicians may increase monitoring frequency if liver tests rise with Jakafi.
No provided excerpt provides liver-test-based monitoring frequency adjustment.
Clinicians may hold Jakafi therapy temporarily if liver tests rise.
Provided excerpts include interrupt/reduce guidance for thrombocytopenia/ANC and a generic approach for other issues, but do not provide liver-test-based hold instructions.
Clinicians may reduce the dose of Jakafi if liver tests rise.
Dose modification for hepatic impairment is referenced, but the excerpt does not state dose reduction based on rising liver tests.
Clinicians may stop Jakafi treatment if significant liver injury is suspected.
No provided excerpt gives stopping guidance for suspected liver injury.
Liver enzyme abnormalities can be more likely in people who already have liver impairment.
Hepatic impairment increases exposure (8.7), but the excerpt does not state that liver enzyme abnormalities are more likely.
The Jakafi label includes guidance on liver-related considerations and how dosing/monitoring may change for patients with hepatic issues.
The excerpt supports dosing modification in hepatic impairment (2.7, 8.7) but does not support 'monitoring' guidance being described as such for liver-related considerations in the provided text.
Serious liver injury with Jakafi is uncommon.
No provided excerpt provides incidence/frequency for serious liver injury.
Most cases of enzyme elevations during Jakafi treatment are identified early via monitoring and managed with dose adjustments.
No provided excerpt provides information about timing of identification via liver monitoring or management outcomes for liver enzyme elevations.
The Jakafi prescribing information does not suggest that liver damage is guaranteed.
This is a negative claim about what the label does not suggest; the provided excerpts do not allow verifying this framing.
The Jakafi prescribing information does not suggest that liver damage is usually permanent.
This is a negative claim about permanence; the provided excerpts do not mention permanence of liver damage.
Contradictions
Low
AI Statement
The Jakafi prescribing information does not suggest that liver damage is usually permanent.
Label Reference
Not verifiable from provided excerpts; no direct contradiction can be established.
Important Omissions
Exact label statements for liver-related adverse reactions and the specific monitoring schedule/criteria for liver tests (e.g., ALT/AST/bilirubin) and associated dose interruption/reduction thresholds for liver abnormalities.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Because several liver-related monitoring and management claims are unsupported by the provided excerpts, the response could misrepresent label-specific monitoring/holding rules. However, the claims are broadly plausible and do not include explicit dosing amounts or contraindications that would directly enable unsafe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple detailed liver-enzyme specifics (ALT/AST/bilirubin), frequency ('less commonly', 'uncommon'), monitoring emphasis for liver tests, and liver-test-based interruption/cessation guidance are not supported by the provided label excerpts.
Suggested Improvement
Limit liver-related statements to what is explicitly present in the provided excerpts: hepatic impairment affects exposure and requires hepatic impairment dosage modification guidance (2.7, 8.7). Avoid specifying ALT/AST/bilirubin or liver-test monitoring schedules and dose-hold/stop actions unless those exact label details are provided.